EP1887362A1 - Vorrichtung, verfahren, system, programm und aufzeichnungsmedium zur einstufung einer leberkrankheit - Google Patents

Vorrichtung, verfahren, system, programm und aufzeichnungsmedium zur einstufung einer leberkrankheit Download PDF

Info

Publication number
EP1887362A1
EP1887362A1 EP06746698A EP06746698A EP1887362A1 EP 1887362 A1 EP1887362 A1 EP 1887362A1 EP 06746698 A EP06746698 A EP 06746698A EP 06746698 A EP06746698 A EP 06746698A EP 1887362 A1 EP1887362 A1 EP 1887362A1
Authority
EP
European Patent Office
Prior art keywords
index
hepatic
fractional expression
evaluating
hepatic disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06746698A
Other languages
English (en)
French (fr)
Other versions
EP1887362A4 (de
Inventor
Qingwei c/o Ajinomoto Co. Inc. ZHANG
Mitsuo c/o Ajinomoto Co. Inc. TAKAHASHI
Tetsuya c/o Ajinomoto Co. Inc. SUGIMOTO
Yasushi c/o Ajinomoto Co. Inc. NOGUCHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of EP1887362A1 publication Critical patent/EP1887362A1/de
Publication of EP1887362A4 publication Critical patent/EP1887362A4/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Definitions

  • the present invention relates to a hepatic disease-evaluating apparatus, a hepatic disease-evaluating method, a hepatic disease-evaluating system, and a hepatic disease-evaluating program and recording medium that calculate an index indicating the degree of hepatic fibrosis from amino acid concentration data to be evaluated based on an index formula and evaluate the disease state of the hepatic disease to be evaluated based on the index value.
  • the Fischer ratio " (Leu+Val+Ile) ⁇ (Phe+Tyr)” based on blood amino acid concentration (see Nonpatent Literature 4) or the BTR (branched-chain amino acids and tyrosine ratio) ratio, which is a simplified Fischer ratio, " (Leu+Val+Ile) ⁇ Tyr” is used for diagnosis of hepatic encephalopathy in the patient with liver cirrhosis, as an index for use in clinical diagnosis of hepatic disease.
  • An object of the present invention which was made to solve the problems above, is to provide a hepatic disease-evaluating apparatus, a hepatic disease-evaluating method, a hepatic disease-evaluating system, and a hepatic disease-evaluating program and a recording medium carrying the same that allow accurate evaluation of the progress of the disease state of hepatic disease and accurate determination, for example, of whether treatment with interferon/ribavirin combination is needed to patients with a hepatic disease.
  • Another aspect of the present invention is the hepatic disease-evaluating system, wherein the index is the sum of two fractional expressions; the numerator in one fractional expression is any one of Phe and Tyr and the denominator in the one fractional expression is any one of Val, Leu, and Ile; and the numerator in the other fractional expression is the sum of at least one of Thr, Met and Orn and the denominator of the other fractional expression is the sum of at least one of Pro and Gly.
  • hepatic fibrosis of a patient is in the stage of F0, F1, or F2 or in the stage of F3 or F4 more accurately. Specifically, it is also possible to determine whether the hepatic fibrosis of a patient is in the stage of F0, F1, F2 or F3 or in the stage of F4 more accurately.
  • an index of the degree of hepatic fibrosis is calculated from previously obtained amino acid concentration data to be evaluated including amino acid concentration values, based on one or more indices (one index or combination of plurality of indices) (step S-1).
  • the index is obtained by assigning the amino acid concentration values, based on the one or more indices.
  • Data such as defective values and outliers may be removed from the amino acid concentration data before calculation of the index (data filtering.or data editing).
  • the index used in step S-1 is a index newly generated by taking clinical need into consideration, and aimed, in particular, at discriminating two groups "F0, F1, or F2" and “F3 or F4" or two groups “F0, F1, F2, or F3” and "F4" in the progressive stages of hepatic fibrosis.
  • An amino acid having smaller influence on the sum of Phe and Tyr, the sum of Thr, Met, and Orn, the sum of Val, Leu, and Ile, or the sum of Pro and Gly may be added as the variable in the index used in step S-1.
  • the phrase "having smaller influence” means that addition of the amino acid does not deteriorate the determination (discrimination) efficiency of the index.
  • the present system the configuration of the hepatic disease-evaluating system according to the present invention (hereinafter, referred to as the present system) will be described with reference to FIGS. 2 to 11 .
  • the entire configuration of the present system will be described with reference to FIGS. 2 and 3 .
  • FIG. 2 is a diagram showing an example of the entire configuration of the present system.
  • FIG. 3 is a diagram showing another example of the entire configuration of the present system.
  • the present system includes a hepatic disease-evaluating apparatus 100 which evaluates hepatic disease and client apparatuses 200 as information communication terminal apparatuses which provide the amino acid concentration data to be evaluated that are communicatively connected to each other via a network 300.
  • a hepatic disease-evaluating apparatus 100 which evaluates hepatic disease and client apparatuses 200 as information communication terminal apparatuses which provide the amino acid concentration data to be evaluated that are communicatively connected to each other via a network 300.
  • the user information file 106a stores information about users (user information).
  • FIG. 5 is a chart showing an example of the information stored in the user information file 106a.
  • the information stored in the user information file 106a includes user ID (identification) for identifying the user uniquely, user password for authentication of the user, user name, organization ID uniquely identifying the organization of the user, department ID for uniquely identifying the department of the user organization, department name, and electronic mail address of the user that are correlated to each other.
  • the index database 106c stores the indices used in the index-calculating part 102g described below.
  • FIG. 7 is a chart showing an example of the information stored in the index database 106c. As shown in FIG. 7 , the information stored in the index database 106c includes index number identifying each index uniquely and index of fractional expressions having amino acid concentrations as variables, that are correlated to each other.
  • the index file 106d stores the index indicating the degree of hepatic fibrosis calculated in the index-calculating part 102g described below.
  • FIG. 8 is a chart showing an example of the information stored in the index file 106d. As shown in FIG. 8 , the information stored in the index file 106d includes subject (sample) number of each subject to be evaluated, index number, and index value that are correlated to each other.
  • it may store as needed sound files in the WAVE or AIFF (Audio Interchange File Format) Format for transmission to the client apparatuses 200 and image files of still image or motion picture in the JPEG (Joint Photographic Experts Group) or MPEG2 (Moving Picture Experts Group phase 2) format.
  • WAVE Wireless Photographic Experts Group
  • MPEG2 Motion Picture Experts Group phase 2
  • the communication interface 104 allows communication between the hepatic disease-evaluating apparatus 100 and the network 300 (or communication apparatus such as router). Thus, the communication interface 104 has a function to communicate data via a communication line with other terminals.
  • the input/output interface 108 is connected to the input device 112 and the output device 114.
  • a monitor including home television), a speaker, or a printer may be used as the output device 114 (hereinafter, a monitor may be described as the output device 114).
  • a keyboard, a mouse, a microphone, or a monitor functioning as a pointing device together with a mouse may be used as the input device 112.
  • the controlling device 102 has an internal memory storing control programs such as OS (Operating System), programs for various processing procedures, and other needed data, and performs information processing for execution of various processings according to these programs.
  • the controlling device 102 includes mainly an instruction-analyzing part 102a, a browsing processing part 102b, an authentication-processing part 102c, an electronic mail-generating part 102d, a Web page-generating part 102e, a receiving part 102f, an index-calculating part 102g, a disease state-evaluating part 102h, a result outputting part 102i, and a sending part 102j.
  • the controlling device 102 performs data processing (data filtering or data editing) such as removal of data including defective values or many outliers and of variables for the defective value-including data in the amino acid concentration data obtained in the receiving part 102g described below.
  • the disease state-evaluating part 102h may determine (discriminate) whether the progressive stage of hepatic fibrosis to be evaluated is in the stage of F0, F1, F2, or F3 or in the stage of F4, by comparing the index with a previously set particular threshold value (cutoff value).
  • the client apparatus 200 may be realized, as peripheral parts such as printer, monitor, and image scanner connected as needed to information processing apparatus (such as known personal computer, workstation, family computer, Internet TV (Television), or the other information processing terminal (such as PHS (Personal Handyphone System) terminal, mobile phone terminal, mobile unit communication terminal or PDA (Personal Digital Assistants))), and also as software (including programs, data and others) for Web data-browsing function and electronic mail-processing function installed in the information processing apparatus.
  • information processing apparatus such as known personal computer, workstation, family computer, Internet TV (Television), or the other information processing terminal (such as PHS (Personal Handyphone System) terminal, mobile phone terminal, mobile unit communication terminal or PDA (Personal Digital Assistants)
  • PHS Personal Handyphone System
  • PDA Personal Digital Assistants
  • All or part of the controlling device 210 in the client apparatus 200 may be performed by a CPU and programs read and executed by the CPU.
  • ROM 220 or HD 230 computer programs for giving instructions to the CPU and executing various processings together with the OS (Operating System) are recorded in the ROM 220 or HD 230.
  • the computer programs may be stored in an application program server connected via any network to the client apparatus 200, and the client apparatus 200 may download all or part of them as needed. All or any part of the controlling device 210 may be substituted with hardware such as wired-logic.
  • the network 300 has a function to connect the hepatic disease-evaluating apparatus 100, the client apparatuses 200, and the database apparatus 400 mutually, communicatively to each other, and is, for example, the Internet, intranet, or LAN (Local Area Network (both wired/wireless)).
  • LAN Local Area Network (both wired/wireless)
  • the network 300 may be VAN (Value Added Network), personal computer communication network, public telephone network (including both analog and digital), leased line network (including both analog and digital), CATV (Community Antenna Television) network, portable switched network or portable packet-switched network (including IMT2000 (International Mobile Telecommunication 2000) system, GSM (Global System for Mobile Communications) system, or PDC (Personal Digital Cellular)/PDC-P system), wireless calling network, local wireless network such as Bluetooth, PHS network, satellite communication network (including CS (Communication Satellite), BS (Broadcasting Satellite), and ISDB (Integrated Services Digital Broadcasting)), or the like.
  • VAN Value Added Network
  • personal computer communication network public telephone network (including both analog and digital), leased line network (including both analog and digital), CATV (Community Antenna Television) network, portable switched network or portable packet-switched network (including IMT2000 (International Mobile Telecommunication 2000) system, GSM (Global System for Mobile Communications) system, or PDC (Pers
  • FIG. 11 is a block diagram showing an example of the configuration of the database apparatus 400 in the present system, showing conceptually only the region relevant to the present invention.
  • the database apparatus 400 has functions to store, for example, the amino acid concentration data to be evaluated transmitted from the client apparatuses 200, the indices used in the hepatic disease-evaluating apparatus 100, and the evaluation results obtained in the hepatic disease-evaluating apparatus 100.
  • the database apparatus 400 has mainly, a controlling device 402, such as CPU, which controls the entire database apparatus 400 integrally, a communication interface 404 connected to a communication apparatus such as router (not shown in the figure), for example, to a communication line, a memory device 406 storing various data, tables and others, and an input/output interface 408 connected to an input device 412 and an output device 414, and these parts are connected communicatively to each other via any communication channel.
  • the database apparatus 400 is connected to the network 300 communicatively via a communication apparatus such as router and via a wired or wireless communication line such as private line.
  • the memory device 406 is a storage means, and may be, for example, memory apparatus such as RAM or ROM, fixed disk drive such as hard' disk, flexible disk, optical disk, or the like. Various programs, tables, files, web-page files, and others used in various processings are stored in the memory device 406.
  • the communication interface 404 allows communication between the database apparatus 400 and the network 300 (or communication apparatus such as router). Thus, the communication interface 404 has a function to communicate data with other terminal via a communication line.
  • the input/output interface 408 is connected to the input device 412 and the output device 414.
  • a monitor including home television), a speaker, or a printer may be used as the output device 414 (hereinafter, a monitor may be described as the output device 414).
  • a keyboard, a mouse, a microphone, or a monitor functioning as a pointing device together with a mouse may be used as the input device 412.
  • the client apparatus 200 connects itself to the hepatic disease-evaluating apparatus 100 via the network 300, when the user specifies the Web site address (such as URL) provided from the hepatic disease-evaluating apparatus 100, via the input device 250 on the screen displaying Web browser 211.
  • the Web browser 211 sends the Web site's URL using a particular protocol via the communication IF 280, transmits an instruction demanding transmission of the Web page corresponding to the amino acid concentration data transmission screen to the hepatic disease-evaluating apparatus 100 based on the routing of the URL.
  • the authentication-processing part 102c examines the input user ID and password by comparing them with the user ID and user password stored in the user information file 106a for authentication, and the browsing processing part 102b sends the Web data to the client apparatus 200, only when the user is authenticated.
  • the client apparatus 200 is identified with the IP (Internet Protocol) address transmitted from the client apparatus 200 together with the transmission instruction.
  • IP Internet Protocol
  • the client apparatus 200 receives in the receiving part 213 the Web data transmitted from the hepatic disease-evaluating apparatus 100 via the communication IF 280, examines the Web data with the Web browser 211, and displays the amino acid concentration data transmission screen on the monitor 261.
  • the instruction demanding transmission of screen from the client apparatus 200 to the hepatic disease-evaluating apparatus 100, the transmission of the Web data from the hepatic disease-evaluating apparatus 100 to the client apparatus 200 and the display of the Web page in the client apparatus 200 are performed almost similarly, and thus, detailed description will be omitted below.
  • the hepatic disease-evaluating apparatus 100 may analyze the identifier transmitted from the client apparatus 200 and the instruction from the client apparatus 200 in the instruction-analyzing part 102a and send an instruction demanding transmission of the index formula used in calculation of the index to the database apparatus 400; and the database apparatus 400 may analyze the instruction sent form the hepatic disease-evaluating apparatus 100 in the instruction-analyzing part 402a and send the index formula (specifically updated newest index) stored in a particular region of the memory device 406 to the hepatic disease-evaluating apparatus 100 via the communication interface 404.
  • the hepatic disease-evaluating apparatus 100 then receives the amino acid concentration data transmitted from the client apparatuses 200 via the communication interface 104 in the receiving part 102f, stores the received amino acid concentration data in a particular region of the amino acid concentration data file 106b, and executes [3-2. hepatic disease evaluation processing] described below (step SA-3).
  • the sending part 102f of the hepatic disease-evaluating apparatus 100 then sends the evaluation results (evaluation results concerning the disease state of the hepatic disease of the subject to be evaluated) obtained in step SA-3 to the client apparatus 200 that has sent the amino acid concentration data of the subject to be evaluated and the database apparatus 400 (step SA-4).
  • the hepatic disease-evaluating apparatus 100 first generates a Web page for display of evaluation results in the Web page-generating part 102 and stores it in a particular memory region of the memory device 106.
  • the user is authenticated as described above by inputting a predetermined URL (Uniform Resource Locator) into the Web browser 211 of the client apparatus 200 via the input device 250, and the client apparatus 200 sends a Web page browsing instruction to the hepatic disease-evaluating apparatus 100.
  • the hepatic disease-evaluating apparatus 100 then examines the browsing instruction transmitted from the client apparatus 200 in the browsing processing part 102a and reads the Web page out of the memory device 106.
  • the hepatic disease-evaluating apparatus 100 then sends Web data corresponding to the read-out Web page to the client apparatus 200 from the sending part 102f.
  • the hepatic disease-evaluating apparatus 100 may send only the evaluation results or the data same as the Web data sent to the client apparatus 200 to the database apparatus 400.
  • step SB-1 data editing
  • stage F0, F1, or F2 and stage F3 or F4 For clinical purpose, there exists a need for a method of discriminating the progressive stage of fibrosis and determining whether the treatment with interferon/ribavirin combination is needed. In particular, there is a need for discriminating two groups: stage F0, F1, or F2 and stage F3 or F4, or stage F0, F1, F2, or F3 and stage F4.
  • hepatic fibrosis of a patient is in the stage of F0, F1, or F2 or in the stage of F3 or F4 more accurately.
  • the hepatic disease includes at least one of hepatitis, chronic hepatitis, hepatic fibrosis and liver cirrhosis, and thus, it is possible to apply the present invention suitably to clinically, .frequently required evaluation of the disease state of at least one of diseases such as hepatitis, chronic hepatitis, hepatic fibrosis and liver cirrhosis.
  • the "program” is a data processing method written in any language or by any description method and may be of any format such as source code or binary code.
  • the "program” may not be an independent program, and may be operated together with plurality of modules and libraries or with a different program such as OS (Operating System).
  • the program is stored on a recording medium and read mechanically as needed by the hepatic disease-evaluating apparatus 100. Any well-known configuration or procedure may be used for reading the programs recorded on the recording medium in each apparatus and for reading procedure and installation of the procedure after reading.
  • the “recording media” includes any “portable physical media”, “fixed physical media”, and “communication media”.
  • Examples of the “portable physical media” include flexible disk, magnetic optical disk, ROM, EPROM (Erasable Programmable Read Only Memory), EEPROM (Electronically Erasable and Programmable Read Only Memory), CD-ROM (Compact Disk Read Only Memory), MO (Magneto-Optical disk), DVD (Digital Versatile Disk), and the like.
  • Examples of the "fixed physical media” include various media installed in a computer system such as ROM, RAM, and HD.
  • the “communication media” are, for example, media storing the program for a short period of time such as communication line and carrier wave when the program is transmitted via a network such as LAN (Local Area Network), WAN (Wide Area Network), or the Internet.
  • the sensitivity was 89%; the specificity, 88%; the positive predictive value, 79%; and the negative predictive value, 88%, in discrimination of two groups "F0, F1, or F2" and "F3 or F4" by using the index 1, when the cutoff value was 0.95.
  • the index 1 was found to be a useful index higher in diagnostic performance in discrimination of two groups "F0, F1, or F2" and "F3 or F4" (especially, superior in diagnostic performance to the Fischer ratio).
  • the hepatic disease-evaluating apparatus, the hepatic disease-evaluating method, the hepatic disease-evaluating system, and the hepatic disease-evaluating program and recording medium according to the present invention are applicable to many industrial fields, especially in pharmaceutical, food, and medical fields, and are extremely useful particularly in the field of bioinformatics field of performing disease state prediction, disease risk prediction, proteome/metabolome analysis, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP06746698A 2005-05-30 2006-05-22 Vorrichtung, verfahren, system, programm und aufzeichnungsmedium zur einstufung einer leberkrankheit Withdrawn EP1887362A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005157802 2005-05-30
PCT/JP2006/310164 WO2006129513A1 (ja) 2005-05-30 2006-05-22 肝疾患評価装置、肝疾患評価方法、肝疾患評価システム、肝疾患評価プログラムおよび記録媒体

Publications (2)

Publication Number Publication Date
EP1887362A1 true EP1887362A1 (de) 2008-02-13
EP1887362A4 EP1887362A4 (de) 2010-01-27

Family

ID=37481442

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06746698A Withdrawn EP1887362A4 (de) 2005-05-30 2006-05-22 Vorrichtung, verfahren, system, programm und aufzeichnungsmedium zur einstufung einer leberkrankheit

Country Status (4)

Country Link
US (1) US8244476B2 (de)
EP (1) EP1887362A4 (de)
JP (1) JPWO2006129513A1 (de)
WO (1) WO2006129513A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010106140A1 (en) 2009-03-19 2010-09-23 Universite D'angers Non-invasive method for assessing liver fibrosis progression
CN102653552A (zh) * 2011-03-02 2012-09-05 上海交通大学附属第一人民医院 慢性乙型肝炎肝纤维化的血清多肽标记物及其检测方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016111A1 (fr) 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Procédé permettant d'évaluer un cancer du poumon, dispositif d'évaluation d'un cancer du poumon, procédé d'évaluation d'un cancer du poumon, système d'évaluation d'un cancer du poumon, programme d'évaluation d'
EP2053405A4 (de) * 2006-08-04 2009-11-11 Ajinomoto Kk Verfahren zur bewertung von stress, stressbewertungsvorrichtung, stressbewertungsverfahren, stressbewertungssystem, stressbewertungsprogramm und aufzeichnungsmedium
WO2008075663A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体
JP5746810B2 (ja) 2006-12-21 2015-07-08 味の素株式会社 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
JPWO2009001862A1 (ja) * 2007-06-25 2010-08-26 味の素株式会社 内臓脂肪蓄積の評価方法
JPWO2009054351A1 (ja) * 2007-10-25 2011-03-03 味の素株式会社 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラムおよび記録媒体
EP2209001A4 (de) * 2007-10-25 2010-10-27 Ajinomoto Kk Verfahren zur beurteilung von gestörter glucosetoleranz
CN102066946B (zh) 2008-06-20 2016-08-31 味之素株式会社 前列腺疾病的评价方法
EP2380018A1 (de) * 2008-12-18 2011-10-26 University Of Utah Systeme und verfahren zur klassifizierung und durchsuchung biologischer materialien zur verwendung für therapie- und/oder forschungszwecke
US20100280986A1 (en) * 2009-05-04 2010-11-04 Roche Palo Alto Systems and methods for tailoring acute and chronic viral infection treatments to increase the probability of "cure" for a given subject
CA2799032A1 (en) * 2010-06-10 2012-01-05 Metanomics Health Gmbh Methods to diagnose liver diseases
JP6260275B2 (ja) * 2011-06-30 2018-01-17 味の素株式会社 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置
WO2013011919A1 (ja) * 2011-07-15 2013-01-24 味の素株式会社 Ｎａｓｈの評価方法、ｎａｓｈ評価装置、ｎａｓｈ評価方法、ｎａｓｈ評価プログラム、ｎａｓｈ評価システム、情報通信端末装置、およびｎａｓｈの予防・改善物質の探索方法
JP5234474B1 (ja) 2012-01-30 2013-07-10 富山県 新規ｌ−アミノ酸オキシダーゼ、ｌ−リジンの測定方法、キット及び酵素センサ
KR102427924B1 (ko) * 2016-10-04 2022-08-02 아지노모토 가부시키가이샤 췌장암의 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치
KR102477319B1 (ko) * 2016-12-01 2022-12-15 아지노모토 가부시키가이샤 암 모니터링의 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 평가 시스템, 및 단말 장치
WO2024237258A1 (ja) * 2023-05-17 2024-11-21 株式会社島津製作所 非アルコール性脂肪肝疾患の識別方法、および、バイオマーカー

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61126472A (ja) * 1984-11-24 1986-06-13 Advance Res & Dev Co Ltd 診断方法
US20040022827A1 (en) * 1997-09-30 2004-02-05 Chugai Seiyaku Kabusiki Kaisha Remedy for hepatopathy
JP2000298131A (ja) 1999-04-14 2000-10-24 Ryuzo Kawamori 前糖尿病状態の検出方法
JP3975279B2 (ja) 1999-11-01 2007-09-12 旭化成ファーマ株式会社 糖尿病予備群の検査方法
US6865415B2 (en) 2000-04-18 2005-03-08 Yamato Scale Co., Ltd. Visceral fat determining device
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
AU2003227237A1 (en) 2002-03-29 2003-10-13 Asahi Kasei Pharma Corporation Method of detecting mild impaired glucose tolerance or insulin hyposecretion
AU2003289263A1 (en) 2002-12-09 2004-06-30 Ajinomoto Co., Inc. Organism condition information processor, organism condition information processing method, organism condition information managing system, program, and recording medium
WO2006098192A1 (ja) 2005-03-16 2006-09-21 Ajinomoto Co., Inc. 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラム、評価関数作成装置、評価関数作成方法、評価関数作成プログラムおよび記録媒体
BRPI0617332A2 (pt) 2005-10-11 2011-07-26 Tethys Bioscience Inc marcadores asoociados ao diabetes e mÉtodos de uso dos mesmos
JPWO2009001862A1 (ja) 2007-06-25 2010-08-26 味の素株式会社 内臓脂肪蓄積の評価方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006129513A1 *
ZHANG Q ET AL: "Plasma amino acid profiles applied for diagnosis of advanced liver fibrosis in patients with chronic hepatitis C infection" HEPATOLOGY RESEARCH, AMSTERDAM, NL, vol. 34, no. 3, 1 March 2006 (2006-03-01), pages 170-177, XP025177439 ISSN: 1386-6346 [retrieved on 2006-03-01] *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010106140A1 (en) 2009-03-19 2010-09-23 Universite D'angers Non-invasive method for assessing liver fibrosis progression
US10861582B2 (en) 2009-03-19 2020-12-08 Centre Hospitalier Universitaire D'angers Non-invasive method for assessing liver fibrosis progression
CN102653552A (zh) * 2011-03-02 2012-09-05 上海交通大学附属第一人民医院 慢性乙型肝炎肝纤维化的血清多肽标记物及其检测方法
CN102653552B (zh) * 2011-03-02 2015-01-07 上海交通大学附属第一人民医院 慢性乙型肝炎肝纤维化的血清多肽标记物及其检测方法

Also Published As

Publication number Publication date
US20080154515A1 (en) 2008-06-26
EP1887362A4 (de) 2010-01-27
JPWO2006129513A1 (ja) 2008-12-25
US20110282585A9 (en) 2011-11-17
WO2006129513A1 (ja) 2006-12-07
US8244476B2 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
US8244476B2 (en) Hepatic disease-evaluating apparatus, hepatic disease-evaluating method, hepatic disease-evaluating system, hepatic disease-evaluating program and recording medium
US9599618B2 (en) Method, apparatus, system, program, and computer-readable recording medium for evaluating colorectal cancer
EP1862797A1 (de) Vorrichtung, verfahren, system und programm zur bewertung biologischer zustände, vorrichtung, verfahren und programm zur erzeugung einer bewertungsfunktion sowie aufzeichnungsmedium
US8673647B2 (en) Stress evaluating apparatus, method, system and program and recording medium therefor
US9664681B2 (en) Lung cancer evaluating apparatus, method, system, and program and recording medium therefor
US9182407B2 (en) Method of evaluating visceral fat accumulation, visceral fat accumulation-evaluating apparatus, visceral fat accumulation-evaluating method, visceral fat accumulation-evaluating system, visceral fat accumulation-evaluating program, recording medium, and method of searching for prophylactic/ameliorating substance for visceral fat accumulation
EP2103941A1 (de) Verfahren zur bewertung von krebs, krebsbewertungsvorrichtung, -verfahren, -system, -programm und aufzeichnungsmedium
US20140127819A1 (en) Method of evaluating nash, nash-evaluating apparatus, nash-evaluating method, nash-evaluating product, nash-evaluating system, information communication terminal apparatus, method of searching for preventing/ameliorating substance for nash
EP2053395A1 (de) Stoffwechselsyndrom-bewertungsverfahren, stoffwechselsyndrom-bewertungsvorrichtung, stoffwechselsyndrom-bewertungsverfahren, stoffwechselsyndrom-bewertungssystem, stoffwechselsyndrom-bewertungsprogramm und aufzeichnungsmedium sowie verfahren zur suche nach einer prophylaktischen/lindernden substanz für stoffwechselsyndrom
US9459255B2 (en) Method of evaluating breast cancer, breast cancer-evaluating apparatus, breast cancer-evaluating method, breast cancer-evaluating system, breast cancer-evaluating program and recording medium
US20110035156A1 (en) Method of evaluating gastric cancer, gastric cancer-evaluating apparatus, gastric cancer-evaluating method, gastric cancer-evaluating system, gastric cancer-evaluating program and recording medium
US20110138889A1 (en) Method of evaluating prostatic disease
US9971866B2 (en) Method of evaluating fatty liver related disease, fatty liver related disease-evaluating apparatus, fatty liver related disease-evaluating method, fatty liver related disease-evaluating program product, fatty liver related disease-evaluating system, information communication terminal apparatus, and method of searching for prophylactic/ameliorating substance for fatty liver related disease
JPWO2009054351A1 (ja) 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラムおよび記録媒体
EP2124059A1 (de) Verfahren zur bewertung von ibd, aminosäuredatenverarbeitungsgerät, aminosäuredatenverarbeitungsverfahren, aminosäuredatenverarbeitungssystem, aminosäuredatenverarbeitungsprogramm und aufzeichnungsmedium
EP2209001A1 (de) Verfahren zur beurteilung von gestörter glucosetoleranz
JP2013178239A (ja) 早期腎症の評価方法、早期腎症評価装置、早期腎症評価方法、早期腎症評価プログラム、早期腎症評価システムおよび情報通信端末装置
KR20170132303A (ko) 평가 방법, 평가 장치, 평가 프로그램 제품, 평가 시스템, 및 단말 장치
JP2013178238A (ja) 心血管イベントの評価方法、心血管イベント評価装置、心血管イベント評価方法、心血管イベント評価プログラム、心血管イベント評価システムおよび情報通信端末装置
Dunphy et al. Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread
Vrana et al. Diagnosis and classification of amyloidosis in abdominal subcutaneous fat aspiration specimens using mass spectrometry based proteomics
States et al. Pilot Phase Results of the Human Proteome Organization Plasma Proteome Project.
Bergen III et al. Monitoring Minimum Residual Disease In Multiple Myeloma Patients By LC-MS/MS
Weissinger et al. Prospective Evaluation of Graft-Versus-Host Disease-Specific Proteomics Pattern in Patients after Allogeneic Stem Cell Transplantation.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20091229

17Q First examination report despatched

Effective date: 20100414

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111229